FINANCIAL STATEMENTS Notes to the financial statements continued 21.
Borrowings continued Terms and debt repayment schedule The maturity date is the date on which the relevant bank loans are due to be fully repaid, as at the balance sheet date.
The carrying amounts drawn after issue costs and including interest accrued under facilities in place at the balance sheet date were as follows: million Maturity Margin over LIBOR 2016 2015 Senior finance facility July 2019 2.00% 424.1 423.1 Revolving credit facility undrawn committed facility 100.0 100.0 On 23 July 2014, the Group was refinanced, and it entered into a bank loan facility with a syndicate of banks, comprising a five-year, 425.0 million term loan and a five-year 100.0 million revolving facility.
The loan is non-amortising and carries interest at a margin of 2.00% over LIBOR 2015: 2.00% over LIBOR.
Reconciliation of net change in cash and cash equivalents to net debt million 2016 2015 Borrowings at start of year Bank loans 423.1 422.2 Obligations under finance leases 75.3 76.6 498.4 498.8 Cash at bank 42.8 65.4 Short-term investments 36.1 9.1 Net debt at 1 January 419.5 424.3 Net decrease increase in cash and cash equivalents 11.0 4.4 Loans movement 1.0 0.9 Movement in obligations under finance leases 0.8 1.3 12.8 4.8 Net debt at 31 December 432.3 419.5 22.
Provisions The movement for the year in the provisions is as follows: Business Medical restructuring million malpractice and other Total At 1 January 2015 4.8 1.3 6.1 Utilised 2.8 0.7 3.5 Additions 7.9 0.6 8.5 Cash received for settlement of claims 4.5 4.5 At 1 January 2016 14.4 1.2 15.6 Utilised 2.2 0.3 2.5 Additions 2.1 1.5 3.6 At 31 December 2016 14.3 2.4 16.7 Medical Malpractice relates to commitments to patients in respect of the removal or replacement of the PIP brand of breast implants, and estimated liabilities arising from claims for damages in respect of services previously supplied to patients.
Amounts are shown gross of insured liabilities.
Any such insurance recoveries are recognised in other receivables.
Business restructuring and other includes staff restructuring costs and the closure costs relating to an onerous contract.
The provisions are shown gross of any expected reimbursement from insurers of the related risks.
The reimbursement is recognised as a separate receivable when receipt of it is judged sufficiently probable.
The amount included in other receivables in that respect was 6.7 million 2015: 6.2 million.
Provisions as at 31 December 2016 are expected to be utilised within three years.
124 Spire Healthcare Group plc Annual Report 2016
